secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034889
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q3 2024 net loss $4.8M; cash $46.7M; RewinD-LB data due Dec 2024
--------------------------------------------------------------------------------

- Net loss $4.8M in Q3 2024 vs net income $2.2M in Q3 2023; R&D expenses rose to $5.1M from $1.8M.
- Cash, cash equivalents and marketable securities $46.7M at Sep 30, 2024 (vs $50.9M at Jun 30); cash runway through 2025.
- RewinD-LB Phase 2b top-line data expected Dec 2024; last patient visit Oct 2024. Plan Phase 3 mid-2025 and Phase 2a for stroke Q1 2025.
- Awarded Prix Galien USA 2024 Best Startup on Nov 8, 2024, recognizing innovation in DLB treatment development.
- Appointed Claudia Ordonez (SVP Medical) and Mark De Rosch (SVP Regulatory); granted options for 56,959 shares at $12.53.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/0001437749-24-034889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774924034889/crvo20241113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer